The approval covers IV and subcutaneous pembrolizumab and raises the TMB-H threshold from 10 to 13 mutations/megabase.

The FDA granted accelerated approval to dostarlimab (Jemperli) on October 19, 2026, for adults with stage II/III locally ...

Alongside urinary symptoms, the regimen can cause systemic effects such as chills, fever, and musculoskeletal pain. Eppie ...

Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS ...

Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib ...

Oral vitamin C at 1000 mg daily for 12 months did not slow clonal growth in adults with clonal cytopenia of undetermined ...

NP Theresa Stukus and NP Nelli Zafman conclude the discussion by reflecting on the resources, practice changes, and ...

Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.

For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker ...

European survey reveals how oncology nurses manage complex multiple myeloma care amid time and resource constraints. Keeping pace with innovation requires nurses to balance a growing volume of ...

Breast cancer survivors are increasingly asking their care teams about glucagon-like peptide-1 (GLP-1) receptor agonists, and two nurses at Winship Cancer Institute of Emory University say the most ...

Among patients with bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) who achieved a complete response (CR) with nogapendekin alfa ...